ReviewFuture medicinal chemistry2025
Therapeutic potential of morpholine-based compounds in neurodegenerative diseases: SAR insights and analysis.
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases are progressive conditions marked by the deterioration of neuronal structure and function, often resulting from enzyme dysregulation and disrupted cellular communication, necessitating innovative treatment approaches. Morpholine, a versatile heterocyclic compound, has gained attention for its broad pharmacological activities and its role in modulating critical enzymes implicated in neurodegenerative processes, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidases (MAO-A and MAO-B). This review presents a structure-based approach to understanding and optimizing morpholine-clubbed heterocycles, offering insights into SAR, synthetic strategies, and pharmacokinetics to facilitate the rational design of anti-neurodegenerative agents. By compiling and analyzing recent advancements (2019-2024), we identify key molecular features that enhance the efficacy, selectivity, and drug likeliness of the derivatives, which are crucial for drug development. Additionally, we discuss an overview of synthetic approaches to prepare diversely functionalized morpholine hybrids, enabling the design of novel and more effective derivatives of enhanced therapeutic potency. Our coverage of various pharmacokinetics properties and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.